Shares of Veru Inc (NASDAQ:VERU) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.04 and traded as high as $2.25. Veru shares last traded at $2.20, with a volume of 3,961 shares changing hands.
A number of research firms have commented on VERU. Zacks Investment Research lowered shares of Veru from a “hold” rating to a “sell” rating in a report on Saturday, October 12th. HC Wainwright reissued a “buy” rating on shares of Veru in a research note on Thursday, October 3rd. Finally, ValuEngine upgraded Veru from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $5.71.
The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $144.71 million, a P/E ratio of -5.71 and a beta of 0.38. The business has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.04.
Several institutional investors and hedge funds have recently added to or reduced their stakes in VERU. Tower Research Capital LLC TRC acquired a new stake in Veru during the 3rd quarter worth $25,000. Squarepoint Ops LLC acquired a new position in Veru in the third quarter valued at about $39,000. Wedge Capital Management L L P NC acquired a new position in Veru in the second quarter valued at about $394,000. BlackRock Inc. grew its stake in Veru by 65.4% in the second quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after acquiring an additional 90,530 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Veru by 183.1% in the second quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock worth $558,000 after acquiring an additional 169,550 shares in the last quarter. Institutional investors and hedge funds own 9.76% of the company’s stock.
About Veru (NASDAQ:VERU)
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Article: Hold Rating
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.